{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-297554","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2026-07-07T20:38:54+00:00","discovered_at":"2026-07-07T20:40:00.325933+00:00","generated_at":"2026-07-07T20:40:04.407521+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ARS Pharmaceuticals appoints Donn Casale as CEO, replacing Richard Lowenthal terminated without cause","bullets":["Donn Casale, previously President, appointed CEO effective July 7, 2026.","Richard Lowenthal terminated without cause on July 6, 2026.","Casale also appointed to Board as Class III director until 2029 annual meeting.","No details on compensation or transition provided in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-297554","json":"https://secwatch.observer/filing/0001193125-26-297554.json","markdown":"https://secwatch.observer/filing/0001193125-26-297554.md","text":"https://secwatch.observer/filing/0001193125-26-297554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/0001193125-26-297554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/d157645d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T20:40:04.407521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0fd1a2015f","claim":"Donn Casale was appointed as Chief Executive Officer at ARS Pharmaceuticals, Inc..","evidence_excerpt":"On July 7, 2026, the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc. (the “Company”) appointed the Company’s current President Donn Casale as the Company’s Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/0001193125-26-297554-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"57cd91dcf4","claim":"Donn Casale was appointed as Class III director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Mr. Casale was also concurrently appointed to the Board as a Class III director, to serve until the Company’s 2029 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/0001193125-26-297554-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"},{"claim_id":"ce1d23ea53","claim":"Richard Lowenthal departed as Chief Executive Officer at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Mr. Lowenthal was notified on July 6, 2026 that his employment was being terminated without cause, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/0001193125-26-297554-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated without cause"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}